by arthroscopy of RA patients before starting anti-TNF therapy. The clinical response was determined after 20 weeks of therapy using the EULAR criteria. The genes most significantly associated with the anti-TNF response were validated by quantitative RT-PCR. Changes in ST protein expression induced by anti-TNF therapy were quantified by immunochemistry and Digital Image Analysis. Results: Eleven RA patients were included and a total of 135 genes were found to be differentially expressed between responders and non-responders after multiple test correction. The functional analysis of the overexpressed genes in the non-responder group (n ¼ 76 genes) identified a highly significant enrichment of genes expressed in peripheral blood CD14þ monocytes (similarity score Kappa ¼ 1.00, P ¼ 3.56e-5). We validated by RT-PCR the genes showing the most significant differential expression: PIK3CD (P ¼ 7.11E-18) and CX3CL1 (P ¼ 7.39E-12). Synovial tissue expression of PIK3CD protein before and after 5 months of anti-TNF therapy showed a significant reduction (P ¼ 0.035) only in those patients with a positive clinical response. Conclusion: Our findings suggest that PIK3CD could be a useful biomarker of response to TNF blockade. Background: The origin of the cells that contribute to skin fibrosis is unclear. Herein, we assess the contribution of sox2-expressing skin progenitor cells to bleomycin-induced skin fibrosis/scleroderma. Methods: We subject wild-type mice and mice in which CCN2 is deleted in sox2-expressing cells to bleomycin-induced skin fibrosis/ scleroderma. We also conduct immunohistochemical and lineage tracing analysis to assess whether cells expressing sox2 are recruited to fibrotic lesions in response to bleomycin-induced fibrosis/ scleroderma. Results: In response to bleomycin, sox2-positive/a-smooth muscle actin-positive cells are recruited to fibrotic tissue (N ¼ 6, P < 0.05). Conditional CCN2 knockout mice in which CCN2 is deleted in sox2-expressing cells exhibit resistance to bleomycin-induced skin fibrosis (N ¼ 6, P < 0.05). Collectively, these results indicate that CCN2 is required for the recruitment of progenitor cells and that CCN2-expressing progenitor cells are essential for bleomycin induced skin fibrosis. Lineage tracing using mice in which a tamoxifen-dependent cre recombinase is expressed under the control of the sox2 promoter confirm that progenitor cells are recruited to the fibrotic lesion in response to bleomycin, but not in CCN2-knockout mice (N ¼ 6, P < 0.05). CCN2 is required for the ability of serum to induce myofibroblast differentiation (a-smooth muscle actin mRNA expression) in skin progenitor cells. (N ¼ 3, P < 0.05). Conclusion: Sox2-positive skin progenitor cells are required for bleomycin-induced skin fibrosis and CCN2 is required for their recruitment to the fibrotic lesion. Targeting stem cell recruitment or CCN2 may therefore represent useful targets in combating fibrotic skin disease such as in scleroderma. Background: OA is a chronic debilitating condition marked by cartilage destruction and bone remodelling. Histopathologically OA is characterized by changes to the tidemark mineralization front, which marks the interface between the superficial viscoelastic hyaline layer and the deep calcified layer. Tidemark duplication (therefore,
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Background: The origin of the cells that contribute to skin fibrosis is unclear. Herein, we assess the contribution of sox2-expressing skin progenitor cells to bleomycin-induced skin fibrosis/scleroderma. Methods: We subject wild-type mice and mice in which CCN2 is deleted in sox2-expressing cells to bleomycin-induced skin fibrosis/ scleroderma. We also conduct immunohistochemical and lineage tracing analysis to assess whether cells expressing sox2 are recruited to fibrotic lesions in response to bleomycin-induced fibrosis/ scleroderma. Results: In response to bleomycin, sox2-positive/a-smooth muscle actin-positive cells are recruited to fibrotic tissue (N ¼ 6, P < 0.05). Conditional CCN2 knockout mice in which CCN2 is deleted in sox2-expressing cells exhibit resistance to bleomycin-induced skin fibrosis (N ¼ 6, P < 0.05). Collectively, these results indicate that CCN2 is required for the recruitment of progenitor cells and that CCN2-expressing progenitor cells are essential for bleomycin induced skin fibrosis. Lineage tracing using mice in which a tamoxifen-dependent cre recombinase is expressed under the control of the sox2 promoter confirm that progenitor cells are recruited to the fibrotic lesion in response to bleomycin, but not in CCN2-knockout mice (N ¼ 6, P < 0.05). CCN2 is required for the ability of serum to induce myofibroblast differentiation (a-smooth muscle actin mRNA expression) in skin progenitor cells. (N ¼ 3, P < 0.05). Conclusion: Sox2-positive skin progenitor cells are required for bleomycin-induced skin fibrosis and CCN2 is required for their recruitment to the fibrotic lesion. Targeting stem cell recruitment or CCN2 may therefore represent useful targets in combating fibrotic skin disease such as in scleroderma. Background: OA is a chronic debilitating condition marked by cartilage destruction and bone remodelling. Histopathologically OA is characterized by changes to the tidemark mineralization front, which marks the interface between the superficial viscoelastic hyaline layer and the deep calcified layer. Tidemark duplication (therefore, advancement) is a known histological feature of OA. This has been suggested to be a consequence of the reactivation of endochondral ossification leading to thickening of the calcified cartilage and neovascularization and neoinnervation of the cartilaginous cartilage potentially leading to mechanical pain. Methods: Femoral heads and tibial plateaus were taken from cadavers. Each femoral head was cut into four blocks exposing the articular surface, two superior to the fovea and two inferior. The tibial plateaus were cut into lateral or medial blocks. All blocks were demineralized by immersion in formal saline for a year, then embedded in wax and sliced into sections. These were divided into three even groups stained with toluidine blue, hematoxylin and eosin, and trichrome gomori. Each section was analysed by light microscopy and following the OARSI criteria set out by Pritzker et.al (2006) given a grade 0-6 based on changes to the matrix and/or cells. Student's t-test explored associations between the presence of a dual tidemark and OARSI grade. Odds ratios were calculated for the occurrence of dual tidemarks by OARSI grade as independently defined by matrix and cells. Results: In total, 13 cadavers (8 male, 5 female, mean age 87) were used. Both femoral heads were removed from 5 cadavers, and one femoral head in two separate cadavers. The tibial plateau was removed from 6 different cadavers. 177 sections were produced (femoral heads left n ¼ 72, right n ¼ 72) (tibial plateaus right n ¼ 22, left n ¼ 11). A dual tidemark was associated with a higher OARSI grade than a single tidemark [mean (S.D.) 3.41 (1.59) vs 1.11 (1.04) respectively: P < 0.001]. A matrix with an OARSI score of 3 predicted a 96 fold increase in the association of a dual tidemark (P < 0.0001), whereas cellular changes resulting in an OARSI score 2 predicted a 17.7 fold increase in the occurrence of a dual tidemark (P < 0.001). Conclusion: We have demonstrated (for the first time) early changes in the matrix (OARSI 3) or chondrocytes (OARSI 2) strongly predict a dual tidemark. Pathologically, OA is regarded as a process that occurs from the wear and tear of articular surfaces. Our data suggest that tidemark advancement occurs at an early stage and may perpetuate further osteoarthritic change at the hyaline layer, thus mediating an alternative bottom-up mechanism. Further exploration of this may lead to novel systemic treatment strategies preventing tidemark advancement and thereby disease progression. is a strong risk factor for human lupus. Chronic high-avidity CR3 engagement by natural ligand appears to induce anti-inflammatory signalling, in particular it blocks pro-inflammatory signalling through monocyte Toll-like receptors. CR3 signalling in NK cells is currently unexplored. The small molecule CR3 agonist Leukadherin-1 has shown promising effects in animal models of inflammation with low toxicity. To further explore the potential of Leukadherin-1 as a therapeutic agent for human lupus and other inflammatory disease we examined its effect on ex-vivo monocytes and NK cells. Methods: Healthy genotyped volunteers were recruited from the Cambridge Bioresource (either homozygous for the common R77 variant of CD11b, or the 77H lupus-risk variant). Monocytes and NK cells were isolated and treated with leukadherin prior to the addition of recognized activating stimuli (TLR2 and TLR7/8 agonists for monocytes and IL-12þIL-15/IL-18 for NK cells). After 18 hours, cytokine secretion into the culture medium was quantified by multiplex cytometric bead array. i150 Downloaded from https://academic.oup.com/rheumatology/article-abstract/53/suppl_1/i150/1796155 by guest on 22 December 2018
